Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

New partners and counsels appointed at Vinge’s Stockholm office

Advokat Sofie Bjärtun, advokat Rikard Lindahl, advokat Malin Malm Waerme and advokat Daniel Wendelsson at Vinge’s Stockholm office have been appointed as new partners as of 1 January 2022. The following lawyers have been elected as counsels at Vinge’s Stockholm office: Advokat Stojan Arnerstål, advokat Amanda Knutsson, advokat Jolene Reimerson, advokat Linnéa Sellström and advokat Filip Öhrner.
July 06, 2021

EU climate taxonomy – New regulations concerning companies’ publication of information

According to the European Union’s climate taxonomy, certain organisations must publish to what extent their operations are environmentally sustainable. In order to clarify what information the companies need to report, as well as how this should be done, the EU Commission has prepared a new delegated regulation. Primarily, the delegated regulation establishes relevant financial key ratios and different report precedents.
June 21, 2021

What an employer should know about the New Whistleblowing Act

Why adopt a new Whistleblowing Act when the current act was adopted as late as 2017?
June 15, 2021